R&D Mind the gap: The need for gender-specific outcome measureme... It is well documented that women face delayed diagnoses, mischaracterised symptoms, and experience more years of ill-health compared to men.
R&D Can sound waves ease depression symptoms? Depression affects more than 280 million people worldwide.
R&D Why I'm focused on the trillion-dollar AMR crisis everyone's... AMR demands sustained commitment beyond conventional market incentives.
R&D WeightWatchers’ Scott Honken on rethinking success in the ag... At HLTH Europe, Deep Dive editor Eloise McLennan sat down with Scott Honken, chief commercial officer at WeightWatchers.
R&D Grants for funding pharmaceutical research: Growing without ... Whilst equity investment is likely to be central to the funding strategy of many early-stage biotechs, grant funding can be a very useful alternative.
R&D Precision medicine - closing the loop: What happens after th... We often talk about diagnostics as the gateway to precision medicine. But what happens before and after the test?
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.